Empiric use of amiodarone and sotalol.

Abstract

Several studies have demonstrated that class I antiarrhythmic drugs do not reduce, and may increase, sudden cardiac death mortality and total cardiac mortality. Because of this, alternative drug choices for antiarrhythmic therapy are necessary. Amiodarone has been demonstrated to be an important and effective antiarrhythmic agent, as has sotalol. The purpose of this article is to review the various indications and possible benefits of the empiric use of these 2 antiarrhythmic agents.

• Authors: M Nora, D P Zipes
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 72 Issue 16 Pg. 62F-69F (Nov 26 1993) ISSN: 0002-9149 [Print] United States
• PMID: 8237832 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Sotalol
• Amiodarone

Topics

• Amiodarone (therapeutic use)
• Cardiomyopathy, Hypertrophic (drug therapy)
• Coronary Disease (drug therapy)
• Death, Sudden, Cardiac (prevention & control)
• Heart Diseases (drug therapy)
• Humans
• Sotalol (therapeutic use)
• Tachycardia, Ventricular (prevention & control)